

## NCCN

# Non-Hodgkin's Lymphomas, Version 4.2014

## Clinical Practice Guidelines in Oncology

Andrew D. Zelenetz, MD, PhD; Leo I. Gordon, MD;  
William G. Wierda, MD, PhD; Jeremy S. Abramson, MD;  
Ranjana H. Advani, MD; C. Babis Andreadis, MD, MSCE;  
Nancy Bartlett, MD; John C. Byrd, MD;  
Myron S. Czuczman, MD; Luis E. Fayad, MD;  
Richard I. Fisher, MD; Martha J. Glenn, MD;  
Nancy Lee Harris, MD; Richard T. Hoppe, MD;  
Steven M. Horwitz, MD; Christopher R. Kelsey, MD;

### Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL. (*J Natl Compr Canc Netw* 2014;12:1282–1303)

### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

**Clinical trials:** NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Youn H. Kim, MD; Susan Krivacic, MPAff; Ann S. LaCasce, MD;  
Auayporn Nademanee, MD; Pierluigi Porcu, MD;  
Oliver Press, MD, PhD; Rachel Rabinovitch, MD;  
Nishitha Reddy, MD; Erin Reid, MD; Ayman A. Saad, MD;  
Lubomir Sokol, MD, PhD; Lode J. Swinnen, MB, ChB;  
Christina Tsien, MD; Julie M. Vose, MD, MBA;  
Joachim Yahalom, MD; Nadeem Zafar, MD; Mary Dwyer, MS;  
and Hema Sundar, PhD

## Mantle Cell Lymphoma: Diagnosis

Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed cases of non-Hodgkin's lymphoma (NHL).<sup>1</sup> MCL is readily distinguished from other small lymphocytic lymphomas because of the widespread availability of appropriated diagnostic reagents.<sup>2</sup> A diagnosis can be established through histological examination in combi-

### Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. **The full NCCN Guidelines for Non-Hodgkin's Lymphomas are not printed in this issue of JNCCN but can be accessed online at NCCN.org.**

© National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

### Disclosures for the NCCN Non-Hodgkin's Lymphomas Panel

At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Non-Hodgkin's Lymphomas Panel members can be found on page 1303. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)

These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

## Journal of the National Comprehensive Cancer Network

nation with a immunohistochemistry (IHC) profile consisting of CD5+, CD10–/+, CD20+, CD23–/+, CD43+, and cyclin D1+. Some cases of MCL may be CD5– or CD23+. MCL is characterized by the reciprocal chromosomal translocation t(11;14), resulting in the overexpression of cyclin D1, and a diagnosis of MCL generally requires the expression of cyclin D1.<sup>3</sup> However, cyclin D1– MCL cases with otherwise typical immunophenotype can be observed, although rare (<5% of cases).<sup>4,5</sup> Recent gene expression profiling data suggest that cyclin D1 expression may not be required for the molecular signature of MCL; in these rare cases of MCL negative for cyclin D1 and t(11;14), overexpression of cyclin D2 or cyclin D3 may be observed.<sup>6,7</sup> IHC for cyclin D2 or cyclin D3 is not helpful in establishing the diagnosis of cyclin

D1– MCL because these proteins are also expressed in other B-cell malignancies. A recent study of cyclin D1– MCL showed rearrangements involving the *CCND2* gene in 55% of cases, which was associated with high expression of cyclin D2 mRNA.<sup>8</sup> Gene expression and miRNA profiling showed that the genomic signatures of cyclin D1– MCL cases were similar to those of cyclin D1+ cases.<sup>5,6,8</sup> Nuclear overexpression of the transcription factor SOX11 is observed in almost all cases of MCL, regardless of cyclin D1 expression level, and may potentially aid in differentiating cyclin D1– MCL cases from other B-cell lymphomas.<sup>9,11</sup> The pathologic features and clinical characteristics of cyclin D1– MCL appear to be similar to those of cyclin D1+ cases.<sup>6,8</sup> Thus, in the absence of data suggesting otherwise, cases of

Text cont. on page 1290.

### NCCN Non-Hodgkin's Lymphomas Panel Members

\*Andrew D. Zelenetz, MD, PhD/Chair†P  
Memorial Sloan Kettering Cancer Center

\*Leo I. Gordon, MD/Co-Vice Chair‡  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

\*William G. Wierda, MD, PhD/Co-Vice Chair‡  
The University of Texas MD Anderson Cancer Center

\*Jeremy S. Abramson, MD†‡  
Massachusetts General Hospital Cancer Center

Ranjana H. Advani, MD†  
Stanford Cancer Institute

C. Babis Andreadis, MD, MSCE‡  
UCSF Helen Diller Family Comprehensive Cancer Center

Nancy Bartlett, MD†  
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

John C. Byrd, MD†P  
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Myron S. Czuczman, MD†‡  
Roswell Park Cancer Institute

Luis E. Fayad, MD†‡P  
The University of Texas MD Anderson Cancer Center

Richard I. Fisher, MD‡  
Fox Chase Cancer Center

Martha J. Glenn, MD†‡P  
Huntsman Cancer Institute at the University of Utah

Nancy Lee Harris, MD‡  
Massachusetts General Hospital Cancer Center

Richard T. Hoppe, MD§  
Stanford Cancer Institute

Steven M. Horwitz, MD†P  
Memorial Sloan Kettering Cancer Center

Christopher R. Kelsey, MD§  
Duke Cancer Institute

Youn H. Kim, MD‡  
Stanford Cancer Institute

Susan Krivacic, MPAff¥  
Consultant

Ann S. LaCasce, MD†  
Dana-Farber/Brigham and Women's Cancer Center

\*Auayporn Nademanee, MD†‡ξ  
City of Hope Comprehensive Cancer Center

Pierluigi Porcu, MD‡P  
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

\*Oliver Press, MD, PhD†  
Fred Hutchinson Cancer Research Center/  
Seattle Cancer Care Alliance

Rachel Rabinovitch, MD§  
University of Colorado Cancer Center

Nishitha Reddy, MD‡ξ  
Vanderbilt-Ingram Cancer Center

Erin Reid, MD†  
UC San Diego Moores Cancer Center

Ayman A. Saad, MD‡ξ  
University of Alabama at Birmingham  
Comprehensive Cancer Network

Lubomir Sokol, MD, PhD†‡P§  
Moffitt Cancer Center

Lode J. Swinnen, MB, ChB‡  
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Christina Tsien, MD§  
University of Michigan Comprehensive Cancer Center

Julie M. Vose, MD, MBA‡ξ  
Fred & Pamela Buffett Cancer Center at  
The Nebraska Medical Center

Joachim Yahalom, MD§  
Memorial Sloan Kettering Cancer Center

Nadeem Zafar, MD‡  
St. Jude Children's Research Hospital/  
The University of Tennessee Health Science Center

NCCN Staff: Mary Dwyer, MS, and Hema Sundar, PhD

KEY:

\*Writing Committee Member

Specialties: †Medical Oncology; ‡Hematology/Hematology Oncology; §Radiotherapy/Radiation Oncology; ξBone Marrow Transplantation; ‡Pathology; PInternal Medicine; ‡Dermatology; ¥Patient Advocacy

## DIAGNOSIS

## ESSENTIAL:

- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis<sup>a,b</sup>
  - IHC panel: CD20, CD3, CD5, cyclin D1, CD10, CD21, CD23, BCL2, BCL6, Ki-67<sup>c</sup>
  - or
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10

## USEFUL UNDER CERTAIN CIRCUMSTANCES:

- Molecular analysis to detect: antigen receptor gene rearrangements; CCND1 rearrangements
- Cytogenetics or FISH: t(11;14), t(14;18), CLL panel

## WORKUP

## ESSENTIAL:

- Physical exam: Attention to node-bearing areas, including Waldeyer's ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- Comprehensive metabolic panel
- LDH
- Bone marrow biopsy ± aspirate
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Hepatitis B testing<sup>d</sup> if rituximab contemplated
- MUGA scan/echocardiogram if anthracycline or anthracenedione-based regimen is indicated
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

## USEFUL UNDER CERTAIN CIRCUMSTANCES:

- Endoscopy/colonoscopy<sup>e</sup>
- Neck CT
- Uric acid
- Discussion of fertility issues and sperm banking
- Lumbar puncture (for blastic variant or CNS symptoms)
- Beta-2-microglobulin
- PET-CT scan

\*Available online, in these guidelines, at [NCCN.org](http://NCCN.org)

<sup>a</sup>Typical immunophenotype: CD5+, CD20+, CD43+, CD23-/+, cyclin D1+, CD10-/+. Note: Some cases of MCL may be CD5- or CD23+. If the diagnosis is suspected, cyclin D1 staining or FISH for t(11;14) should be done. There are rare cases of *CCND1*- MCL (<5%) with an otherwise typical immunophenotype.

<sup>b</sup>See Use of Immunophenotyping/Genetic Testing in Differential Diagnosis of Mature B-Cell and NK/T-Cell Neoplasms (NHODG-A\*).

<sup>c</sup>Ki-67 proliferation fraction of <30% is associated with a more favorable prognosis. However, it is not used to guide treatment.


<sup>d</sup>Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B surface antigen and core antibody for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add e-antigen. If positive, check viral load and consult with gastroenterologist.

<sup>e</sup>Essential for confirmation of stage I-II disease. See Discussion for details.

## MANT-1

## Non-Hodgkin's Lymphomas, Version 4.2014

## MANTLE CELL LYMPHOMA



Consider prophylaxis for tumor lysis syndrome (See NHODG-B\*)

See monoclonal antibody and viral reactivation (NHODG-B\*)

\*Available online, in these guidelines, at NCCN.org

<sup>f</sup>Early referral for high-dose therapy with stem cell rescue is advisable for planning purposes.


<sup>g</sup>See Principles of Radiation Therapy (NHODG-D\*).

<sup>h</sup>Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. *Ann Oncol* 2003;14:1555-1561.

<sup>i</sup>See Response Criteria for Non-Hodgkin's Lymphoma (NHODG-C\*).

<sup>j</sup>Option for clinical trials of adjuvant therapy or for relapsed disease involving high-dose therapy with autologous or allogeneic stem cell rescue, immunotherapy with nonmyeloablative stem cell rescue, or evaluation of treatment with new agents are appropriate.

## MANT-2



\*Available online, in these guidelines, at NCCN.org

Consider prophylaxis for tumor lysis syndrome (See NHODG-B\*)  
See monoclonal antibody and viral reactivation (NHODG-B\*)

<sup>f</sup>Early referral for high-dose therapy with stem cell rescue is advisable for planning purposes.  
<sup>i</sup>See Response Criteria for Non-Hodgkin's Lymphoma (NHODG-C\*).  
<sup>j</sup>Option for clinical trials of adjuvant therapy or for relapsed disease involving high-dose therapy with autologous stem cell rescue or allogeneic stem cell transplant, immunotherapy with nonmyeloablative stem cell rescue, or evaluation of treatment with new agents are appropriate.  
<sup>k</sup>Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.

MANT-3

SUGGESTED TREATMENT REGIMENS<sup>a</sup>  
(in alphabetical order)

Induction Therapy

- Aggressive therapy
  - CALGB regimen<sup>b</sup> (Treatment 1, 2, 2.5: rituximab + methotrexate with augmented CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone]; Treatment 3: etoposide, cytarabine, rituximab; Treatment 4: carmustine, etoposide, cyclophosphamide/autologous stem cell rescue; Treatment 5: rituximab maintenance) (Treatment 2.5 is given if the pre-Treatment 3 bone marrow biopsy contains >15% MCL.)
  - HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine) + rituximab
  - NORDIC regimen<sup>b</sup> (dose-intensified induction immunochemotherapy with rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone [maxi-CHOP]) alternating with rituximab + high-dose cytarabine)
  - Alternating RCHOP/RDHAP<sup>b</sup> (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)/(rituximab, dexamethasone, cisplatin, cytarabine)
  - Sequential RCHOP/RICE<sup>b</sup> (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)/(rituximab, ifosfamide, carboplatin, etoposide)
- Less aggressive therapy
  - Bendamustine + rituximab
  - CHOP + rituximab<sup>c</sup> followed by consolidation with rituximab maintenance (375 mg/m<sup>2</sup> every 8 wks until progression) (category 1 for maintenance)
  - Cladribine + rituximab
  - Modified rituximab-HyperCVAD with rituximab maintenance in patients older than 65 y

First-line Consolidation<sup>d</sup>

- Clinical trial
- High-dose therapy with autologous stem cell rescue<sup>e</sup>

Second-line Therapy

- Bendamustine ± rituximab
- Bortezomib ± rituximab
- Cladribine + rituximab
- FC (fludarabine, cyclophosphamide) ± rituximab
- FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)
- FMR (fludarabine, mitoxantrone, rituximab)
- Ibrutinib<sup>f</sup>
- Lenalidomide ± rituximab
- PCR (pentostatin, cyclophosphamide, rituximab)
- PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) ± rituximab
- See Second-line Therapy for DLBCL (BCEL-C 1 of 3) without regard to transplantability

Second-line Consolidation

- Allogeneic stem cell transplant (nonmyeloablative or myeloablative)

\*Available online, in these guidelines, at NCCN.org

<sup>a</sup>See references for regimens MANT-A 2 of 3 and MANT-A 3 of 3.

<sup>b</sup>These regimens include first-line consolidation with high-dose therapy and autologous stem cell rescue (HDT/ASCR).

<sup>c</sup>There is a randomized trial that demonstrated that RCHOP was not superior to CHOP.

<sup>d</sup>Typically patients will receive an aggressive induction regimen prior to consolidation; however, less aggressive regimens followed by consolidation with high-dose therapy may also result in a good long-term outcome.

<sup>e</sup>Randomized data with anthracycline-containing regimens suggest an improvement in progression-free survival with the addition of first-line high-dose therapy with autologous stem cell consolidation.

<sup>f</sup>See Special Considerations for Use of B-Cell Receptor Inhibitors (Ibrutinib and Idelalisib) (NHODG-E; available in these Guidelines at NCCN.org.)

MANT-A  
1 of 3

SUGGESTED TREATMENT REGIMENS  
References
**Induction Therapy****Aggressive therapy****HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine) + rituximab**

Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. *J Clin Oncol* 2005;23:7013-7023.

Merli F, Luminari S, Ilariucci F, et al. Rituximab plus hyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. *Br J Haematol* 2012;156:346-353.

**Nordic trial regimen (Dose-intensified induction immunochemotherapy with rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone [maxi-CHOP]) alternating with rituximab + high-dose cytarabine)**

Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A non-randomized phase-II multicenter study by the Nordic Lymphoma Group. *Blood* 2008;112:2687-2693.

**CALGB regimen**

Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. *J Clin Oncol* 2009;27:6101-6108.

**RCHOP/RICE**

Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. *Ann Oncol* 2010;21:133-139.

**RCHOP/RDHAP**

Pott C, Hoster E, Beldjord K, et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network [abstract]. *Blood* 2010;116:Abstract 965.

Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA. *Blood* 2013;121:48-53.

**Less aggressive therapy****Bendamustine + rituximab**

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet* 2013;381:1203-1210.

**CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab**

Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *J Clin Oncol* 2005;23:1984-1992.

Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. *N Eng J Med* 2012;367:520-531.

**Cladribine + rituximab**

Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. *Cancer* 2008;113:108-116.

Spurgeon SE, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. *Leuk Lymphoma* 2011;52:1488-1494.

**Modified hyperCVAD with rituximab maintenance**

Kahl BS, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. *Ann Oncol* 2006;17:1418-1423.

## SUGGESTED TREATMENT REGIMENS

## References

**First-line Consolidation****High-dose therapy with autologous stem cell rescue**

Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. *Blood* 2005;105:2677-2684.

Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. *Cancer* 2005;104:1434-1441.

Ritchie D, Seymour J, Grigg A, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. *Ann Hematol* 2007;86:101-105.

van 't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. *Br J Haematol* 2009;144:524-530.

**Rituximab maintenance**

Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. *N Engl J Med* 2012;367:520-531.

**Second-line Therapy****Bendamustine**

Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell Non-Hodgkin's Lymphoma. *J Clin Oncol* 2008; 26:4473-4479.

Rummel MJ, Al-Batran SE, Kim S-Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin's lymphoma. *J Clin Oncol* 2005;23:3383-3389.

**Bortezomib**

Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. *Ann Oncol* 2009;20:520-525.

Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. *Cancer* 2011;117:2442-2451.

**Cladribine**

Rummel MJ, Chow KU, Jager E, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. *Ann Oncol* 1999;10:115-117.

Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. *Cancer* 2008;113:108-116.

**FC (fludarabine and cyclophosphamide) ± rituximab**

Cohen BJ, Moskowitz C, Straus D et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. *Leuk Lymphoma* 2001;42:1015-1022.

**FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)**

Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). *Blood* 2004;104:3064-3071.

**FMR (fludarabine, mitoxantrone, rituximab)**

Levine AM, Tulpule A, Smith L, Espina BM, Mohrbacher AF, Feinstein DI. Results of a pilot trial of fludarabine, mitoxantrone and rituxan in mantle cell lymphoma [abstract]. *Blood* 2005;106:Abstract 945.

**Ibrutinib**

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med* 2013;369:507-516.

**Lenalidomide**

Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. *Br J Haematol* 2009;145:344-349.

Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. *Ann Oncol* 2011;22:1622-1627.

Goy A, Sinha R, Williams ME, et al. Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: The MCL-001 "EMERGE" Study [abstract]. *Blood* 2012;120:Abstract 905.

**Lenalidomide + rituximab**

Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. *Lancet Oncol* 2012;13:716-723.

**PEP-C (prednisone, etoposide, procarbazine, cyclophosphamide) ± rituximab**

Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. *Cancer* 2008;112:2228-2232.

Text cont. from page 1283.

cyclin D1– MCL should not be managed differently than cyclin D1+ cases.

Currently available reagents for IHC evaluation of cyclin D1 are robust and yield good staining; however, in some cases, molecular analysis of *CCND1* rearrangements or cytogenetics or FISH for the translocation t(11;14), juxtaposing the cyclin D1 locus with the IgH locus, can be helpful for diagnosis.<sup>12</sup> In certain cases, cytogenetics or FISH for t(14;18) and a FISH panel for chronic lymphocytic leukemia may also be useful. In addition, Ki67 should be included in the IHC panel for initial diagnostic workup. A Ki67 proliferation index of less than 30% has been associated with a more favorable prognosis.<sup>13–17</sup> However, this should not be used to guide treatment decisions at this time.

### In-Situ Involvement of MCL-Like Cells of Unknown Significance (MCL In Situ)

The presence of MCL-like B-cells in the mantle zones of morphologically reactive lymph nodes (MCL in situ) has been described in several case reports (including in patients with lymphoid hyperplasia).<sup>18,19</sup> MCL in situ is characterized by preservation of the lymph node architecture and presence of cyclin D1+ B-cells restricted to the mantle zones with minimal expansion of the mantle zone (and with only minimal or no spread of cyclin D1+ cells in the interfollicular area).<sup>18–21</sup> More recently, a scattering of cyclin D1+ cells in the germinal centers (but not the mantle zones) of a lymph node specimen (retrospectively evaluated several years before the diagnosis of symptomatic MCL) has been reported.<sup>22</sup>

The occurrence of MCL in situ in studies of reactive lymph nodes was very rare.<sup>20,23</sup> In an analysis of a consecutive series of unselected surgical samples of reactive lymph nodes from patients without a history of lymphoma (n=131; 1292 samples), no cases of MCL in situ were identified.<sup>23</sup> Development of overt MCL in patients found to have MCL in situ has been reported, although this appears to be very uncommon.<sup>20</sup> The significance or potential for malignancy of MCL in situ in patients without known MCL remains uncertain. These cases appear to have a very indolent course with long-term survival even without treatment intervention.<sup>20,21</sup> Therefore, distinguishing cases of MCL in situ from cases of overt MCL with a mantle zone pattern is important. In pa-

tients with the former in whom overt MCL can be excluded based on a thorough evaluation (eg, biopsy of additional suspicious nodes, physical examination, peripheral blood flow cytometry, and CT scan of neck, chest, abdomen, and pelvis), close follow-up may still be warranted.<sup>24</sup> The WHO classification recommends that a diagnosis of MCL not be made in such cases.

### Workup

The workup for MCL is similar to the workup for many indolent lymphomas and certain aggressive lymphomas. The initial workup for newly diagnosed MCL should include a thorough physical examination with attention to node-bearing areas and evaluation of performance status and constitutional symptoms. Laboratory assessments should include standard blood work including CBC with differential and a comprehensive metabolic panel, in addition to measurements of serum lactate dehydrogenase (LDH). Patients with high tumor burden and elevated LDH should be assessed for spontaneous tumor lysis syndrome, including measurements of uric acid level. Measurement of serum beta-2 microglobulin levels may also be useful in some circumstances. HBV testing is recommended due to increased risks of viral reactivation when immunotherapy regimens are being considered for treatment. MCL is a systemic disease with frequent involvement of the bone marrow and gastrointestinal (GI) tract and may also present with a leukemic phase. For this reason, both the peripheral blood and bone marrow must be carefully evaluated for the presence of malignant cells. Adequate trephine biopsy should be obtained for initial staging evaluation, with or without bone marrow aspiration. Chest, abdominal, and pelvic CT scans are routinely performed. PET-CT scan and CT scan of the neck may be helpful in selected cases. In patients with the blastic variant or for patients presenting with central nervous system symptoms, a lumbar puncture should be performed to evaluate the cerebral spinal fluid for potential disease involvement.

GI involvement has been reported in 15% to 30% of patients with MCL. In two prospective studies, the frequency of GI tract involvement in patients with MCL was higher than that reported in the literature.<sup>25,26</sup> In the study by Romaguera et al,<sup>25</sup> MCL was histologically present in the lower and

upper GI tract in 88% and 43% of patients, respectively. In this report, 26% of patients presented with GI symptoms at the time of diagnosis. Despite the high frequency of GI tract involvement (which was primarily observed at the microscopic level), the use of endoscopy with biopsies led to changes in clinical management in only 4% of patients.<sup>25</sup> Salar et al<sup>26</sup> reported upper or lower GI tract involvement in 92% of patients at diagnosis. The NCCN Guidelines panel does not recommend endoscopy or colonoscopy as part of routine initial workup but suggests that it may be useful in certain circumstances. However, endoscopic or colonoscopic evaluation of the GI tract is necessary for confirmation of stage I–II disease and for assessment of response to initial therapy.

### Treatment Options Based on Clinical Stage

Generally, MCL is thought to possess the worst characteristics of both indolent and aggressive NHL subtypes because of the incurability of disease with conventional chemotherapy and a more aggressive disease course.<sup>27</sup>

#### Stage I-II

Few patients present with localized MCL, and the available published literature on management is retrospective and anecdotal. In a retrospective analysis of patients with limited bulk, early-stage (stage IA or IIA) MCL (n=26), inclusion of radiation therapy (RT) with or without chemotherapy was associated with significantly improved progression-free survival (PFS) at 5 years (68% vs 11%;  $P = .002$ ) and a trend toward improved overall survival (OS).<sup>28</sup>

#### Stage II (Bulky) and Stage III-IV

Several regimens have shown significant activity in patients with newly diagnosed MCL, but none of these regimens are curative in patients with advanced disease. In a database analysis from a single-center cohort (n=111), Martin et al<sup>29</sup> reported that treatment with regimens including R-CHOP or R-CVP could yield survival outcomes similar to that achieved with more intensive approaches. The median OS from diagnosis was 85 months, and the 5-year OS rate was 66%. Among patients with available data on treatment regimens (n=75), most (70%) had received CHOP-like therapy with or without rituximab; only 7% had received more intensive first-line

therapies (R-hyper-CVAD and/or high-dose therapy with autologous stem cell rescue [HDT/ASCR]).<sup>29</sup>

However, a more recently published analysis from the NCCN Oncology Outcomes Database suggested that median PFS remained 3 to 4 years despite the use of aggressive regimens in patients with MCL (n=167).<sup>30</sup> This analysis reported superior PFS outcomes with R-hyper-CVAD alone or with rituximab-containing regimens (eg, R-CHOP) followed by HDT/ASCR, compared with R-CHOP alone, in the first-line setting for younger patients (<65 years of age) with MCL.<sup>30</sup>

**Aggressive First-Line Therapy:** Rituximab used in combination with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; alternating with high-dose methotrexate and cytarabine) [R-hyper-CVAD] has resulted in favorable PFS and OS outcomes.<sup>31–34</sup>

In a phase II study in previously untreated patients with MCL (n=97), R-hyper-CVAD produced 3-year failure-free survival and OS rates of 64% and 82%, respectively, with a median follow-up time of 40 months.<sup>31</sup> After 10 years of follow-up, the median OS had not been reached and the median time to failure (TTF) was 4.6 years for all patients. Among patients 65 years or younger, the median OS had not been reached and the median TTF was 5.9 years. In the multivariate analysis, pretreatment serum levels of beta-2-microglobulin, International Prognostic Index (IPI) score, and MCL International Prognostic Index (MIPI) score were predictive of both OS and TTF.<sup>32</sup> Failure-free and OS rates were 43% and 60%, respectively; among patients 65 years or younger, the corresponding survival rates were 52% and 68%, respectively.

In the Italian study of 60 evaluable patients, R-hyper-CVAD resulted in an overall response rate of 83% with a complete remission (CR) rate of 72%. The 5-year PFS and OS rates were 61% and 73%, respectively.<sup>33</sup> However, this regimen was associated with substantial toxicity.

In the SWOG 0213 study, R-hyper-CVAD induced CR/CRu (CR unconfirmed) in 58% of previously untreated patients (age <70 years) with MCL (n=49).<sup>34</sup> With a median follow-up of 4.8 years, the median PFS and OS were 4.8 years (5.5 years for those ≤65 years) and 6.8 years, respectively. The 2-year PFS and OS rates were 63% and 76%, respectively.

**Less Aggressive First-Line Therapy:** In the earlier studies, the addition of rituximab to CHOP chemotherapy was associated with high response rates but did not translate to prolonged PFS or OS.<sup>35,36</sup> A phase III randomized trial in the German Low Grade Lymphoma study group evaluated R-CHOP versus CHOP alone in previously untreated patients (age  $\leq 65$  years) with advanced-stage MCL (n=122).<sup>36</sup> In this study, R-CHOP was significantly superior to CHOP in terms of overall response rate (ORR) (94% vs 75%), CR rate (34% vs 7%) and median TTF (21 vs 14 months). However, no differences were observed between treatment arms for PFS or OS outcomes.<sup>36</sup>

Other nonaggressive regimens have also been evaluated in clinical trials. The combination of bendamustine with rituximab (BR regimen) was investigated in a randomized phase III study of the StiL group (Study Group Indolent Lymphomas), which compared BR versus R-CHOP as first-line therapy in patients with advanced follicular, indolent, and MCLs (514 evaluable patients; MCL histology comprised 18% of patients).<sup>37</sup> The ORR was similar in both arms (93% with BR vs 91% with R-CHOP), although the CR rate was significantly higher in the BR arm (40% vs 30%;  $P = .021$ ). With a median follow-up time of 45 months, the BR arm was associated with significantly longer median PFS (primary endpoint) compared with R-CHOP (69.5 vs 31.2 months; HR, 0.58; 95% CI, 0.44–0.74;  $P < .0001$ ); however, OS outcomes were not significantly different between treatment arms. Among the subgroup of patients with MCL histology, median PFS was also significantly higher with BR compared with R-CHOP (35 vs 22 months; HR=0.49; 95% CI, 0.28–0.79;  $P = .0044$ ).<sup>37</sup> The BR regimen was associated with less-frequent serious adverse events (19% vs 29%) and less grade 3 or 4 hematologic toxicities compared with R-CHOP. Grade 3 or 4 neutropenia was reported in 29% in the BR arm and 69% with R-CHOP. Peripheral neuropathy (all grades) was less frequent in the BR arm (7% vs 29%). Infectious complications (all grades) were also less frequent with BR compared with R-CHOP (37% vs 50%). Fatal sepsis occurred in 1 patient in the BR arm and 5 patients in the R-CHOP arm. The BR regimen was more frequently associated with skin toxicities (all grades), including erythema (16% vs 9%) and allergic reactions (15% vs 6%) compared with R-

CHOP.<sup>37</sup> Although this phase III randomized trial showed superior PFS outcomes with the BR regimen compared with R-CHOP, there may be limitations given that data from more than half of the patients in this trial were censored before the minimum follow-up period.

The combination of bendamustine and rituximab with the addition of cytarabine was evaluated in a phase II study in older patients with MCL (age  $\geq 65$  years; not eligible for intensive regimens or HDT/ASCR).<sup>38</sup> Among enrolled patients (n=40; median age, 70 years), 50% were previously untreated, 93% had stage III/IV disease and 49% had high-risk MIPI scores. Patients with relapsed/refractory disease (n=20) had all previously received rituximab-containing therapies.<sup>38</sup> Among previously untreated patients, the ORR was 100% and the 2-year PFS rate was 95%. Among patients with relapsed/refractory disease, the ORR was 70% and the 2-year PFS was 70%. The most common grade 3 or 4 toxicities included transient thrombocytopenia (87%) and febrile neutropenia (12%).<sup>38</sup>

Cladribine, alone or in combination with rituximab, has shown activity in patients with previously untreated MCL.<sup>39–41</sup> In trials conducted by the North Central Cancer Treatment group, the ORR and median PFS for single agent cladribine were 81% (42% CR) and 14 months, respectively, for previously untreated patients (n=26); the combination of cladribine and rituximab as initial therapy (n=29) resulted in an ORR of 66% (52% CR) and median PFS of 12 months.<sup>39</sup> In a small trial in patients with previously untreated and pretreated MCL (n=12), cladribine alone induced an ORR of 58% (25% CR) with a median time to progression of 19 months.<sup>40</sup> In a recent retrospective study in patients with previously untreated MCL (n=31), cladribine combined with rituximab yielded an ORR of 87% (61% CR/CRu) with a median PFS and OS of 37.5 and 85 months, respectively.<sup>41</sup> It should be noted that in this study, most responding patients had received postinduction maintenance therapy with rituximab.

**First-Line Consolidation Therapy:** HDT/ASCR as first-line consolidation has shown promising outcomes in multiple studies.<sup>42–48</sup>

In a prospective study of sequential front-line CHOP/DHAP followed by HDT/ASCR in patients with MCL (n=28; n=23 proceeded to transplant), the 3-year event-free survival (EFS) and OS rates

were 83% and 90%, respectively.<sup>44</sup> Median OS was not reached after a median follow-up of almost 48 months. In a randomized trial conducted by the European MCL Network, patients (age  $\leq$  65 years) with advanced-stage MCL (n=122) in remission after CHOP-like chemotherapy were randomized to receive HDT/ASCR or maintenance with interferon alfa.<sup>45</sup> In this study, HDT/ASCR was associated with a significantly longer median PFS compared with interferon alfa maintenance (39 vs 17 months;  $P=.011$ ). The 3-year OS rates were 83% and 77%, respectively, and were not significantly different between consolidation arms.<sup>45</sup>

In a study conducted by the MD Anderson Cancer Center, HDT/ASCR in patients with MCL (n=33) in first remission after treatment with hyper-CVAD resulted in 5-year disease-free survival and OS rates of 42% and 77%, respectively.<sup>43</sup> In particular, the subgroup of patients with low serum beta-2 microglobulin levels appeared to benefit most, with a 5-year OS rate of 100% (compared with 22% for patients with elevated beta-2 microglobulin).<sup>43</sup> In an analysis of long-term outcomes from patients with MCL treated at the MD Anderson Cancer Center (including the 33 patients reported in the earlier study above), the subgroup of patients treated primarily with hyper-CVAD (with or without rituximab) followed by HDT/ASCR in first remission (n=50) showed a median PFS of 42 months and a median OS of 93 months.<sup>47</sup>

In a small prospective study that evaluated R-hyperCVAD followed by HDT/ASCR in patients with previously untreated MCL (n=13; 12 patients proceeded to transplant), the 3-year EFS and OS rate was 92% for both endpoints.<sup>46</sup> These results with R-hyper-CVAD appear favorable relative to induction with R-CHOP.

In a phase II study that evaluated R-CHOP induction followed by HDT/ASCR in patients with previously untreated MCL (n=87; 61 patients proceeded to transplant), the 4-year failure-free survival and OS rates were 36% and 66%, respectively.<sup>48</sup>

In another study, patients with MCL treated with hyper-CVAD or CHOP (with or without rituximab, in either regimen) followed by HDT/ASCR in first remission (n=36) had 3-year PFS and OS rates of 63% and 93%, respectively.<sup>49</sup> Induction with hyper-CVAD resulted in a higher 3-year PFS rate compared with CHOP (81% vs 44%), although

the difference was not statistically significant. The 3-year OS rate was similar between induction regimens (94% vs 92%, respectively).<sup>49</sup> Disease status at transplant was the most significant factor affecting survival after HDT/ASCR.<sup>49,50</sup> Patients in first remission (CR or partial) at the time of transplant had improved survival outcomes compared with those with relapsed or refractory disease. As mentioned previously, among patients undergoing transplant in first remission, hyper-CVAD (with or without rituximab) induction was associated with an improved PFS outcome compared with CHOP (with or without rituximab) in nonrandomized studies.<sup>49</sup>

Several different induction regimens incorporating rituximab in combination with dose intensified anthracyclinebased<sup>16,51,52</sup> or cladribine-based chemotherapy<sup>53-55</sup> followed by HDT/ASCR have shown promising efficacy in relatively young patients with newly diagnosed MCL.

In the Nordic MCL trial, induction therapy with rituximab and dose intensified CHOP (maxi-CHOP) alternating with high-dose cytarabine resulted in an ORR and CR rate of 96% and 54%, respectively, in previously untreated patients (age  $\leq$ 65 years) with MCL (n=160).<sup>51</sup> Responding patients were eligible to proceed with HDT/ASCR. The 6-year PFS and OS rates were 66% and 70%, respectively, with no relapses occurring after a median follow-up of approximately 4 years (at the time of the initial report).<sup>51</sup> Further follow-up from this study with a median observation time of 6.5 years showed median EFS of 7.4 years; median OS exceeded 10 years.<sup>56</sup> Late relapses were reported in 6 patients, who experienced disease progression more than 5 years after the end of therapy. In the multivariate analysis from this study, the MIPI and ki67 expression level were the only independent predictors of survival outcomes.<sup>56</sup> However, in this trial, patients were monitored using disease-specific primers for molecular relapse, and those who experienced relapse received rituximab as reinduction but were not considered to have relapsed unless there was morphologic evidence of relapse.

The Cancer and Leukemia Group B (CALGB 59909 trial) reported that rituximab in combination with methotrexate and augmented CHOP followed by HDT/ASCR was safe and effective in patients with newly diagnosed MCL (n=78).<sup>52</sup> At a median follow-up of 4.7 years, the 5-year PFS and OS rates were 56% and 64%, respectively.

In patients with newly diagnosed MCL (n=88 evaluable), sequential chemotherapy (CHOP followed by ICE) with or without rituximab followed by consolidation with HDT/ASCR was associated with a superior PFS compared with RIT followed by CHOP (4-year PFS rate: 65% vs 26%); the 4-year OS rate was 84% for both treatment groups.<sup>16</sup> This study also showed the prognostic significance of the proliferation index on PFS outcomes. Moreover, among the subgroup of patients with a proliferation index less than 30%, HDT/ASCR resulted in superior PFS compared with RIT-CHOP (5-year PFS rate: 82% vs 24%).

In the phase III randomized Intergroup trial conducted by the European MCL Network, sequential treatment with 3 cycles each of R-CHOP and R-DHAP followed by HDT/ASCR (using high-dose cytarabine containing myeloablative regimen) induced higher remission rates compared with 6 cycles of R-CHOP followed by HDT/ASCR (using myeloablative radiochemotherapy) in patients (age ≤ 65 years) with advanced stage MCL (391 evaluable patients).<sup>53</sup> The clinical CR rates were 39% and 26%, respectively; median TTF was not reached in the R-CHOP/R-DHAP arm compared with 49 months in the R-CHOP arm, after a median follow-up of 27 months. The rate of molecular remission (MRD-negative status in peripheral blood or bone marrow) was significantly higher in the R-CHOP/R-DHAP arm compared with R-CHOP (73% vs 32%). Achievement of molecular remission in the bone marrow after induction was associated with significantly improved 2-year PFS outcomes in the combined treatment arms.<sup>53</sup> Final analysis from this trial (455 evaluable patients) confirmed that R-CHOP/R-DHAP induction was associated with higher CR rate (36% vs 25%) and CR/CRu rate (54% vs 40%) compared with R-CHOP.<sup>54</sup> After HDT/ASCR, the CR rates were similar between treatment arms (61% vs 63%), although R-CHOP/R-DHAP was associated with longer remission duration (84 vs 49 months;  $P=.0001$ ). After a median follow-up of 51 months, median TTF was significantly longer in the R-CHOP/R-DHAP arm compared with the R-CHOP arm (88 vs 46 months;  $P=.038$ ).<sup>54</sup> Moreover, median OS was longer in the R-CHOP/R-DHAP arm (not reached vs 82 months;  $P=.045$ ). The investigators concluded that an induction regimen containing high-dose cytarabine in addition to R-CHOP resulted in improved outcomes and suggested that these regi-

mens followed by HDT/ASCR may define a new standard for the treatment of younger patients (<65 years of age) with MCL.<sup>54</sup>

In a phase II multicenter trial of the French cooperative group GELA, induction with 3 cycles each of R-CHOP and R-DHAP resulted in an ORR of 95% with CR in 57% of patients (age ≤ 65 years) with previously untreated MCL (n=60).<sup>55</sup> Patients went on to receive HDT/ASCR on this study. After a median follow-up of 67 months, the median EFS was 83 months and median OS has not been reached; the 5-year OS was 75%.<sup>55</sup>

**Postinduction Maintenance Therapy:** Maintenance therapy with rituximab may provide extended disease control for patients who are not physically fit or not eligible to undergo aggressive first-line treatment regimens and HDT/ASCR.<sup>57-59</sup>

In a small phase II pilot study in previously untreated patients (n=22), a less intensive, modified R-hyperCVAD regimen (without methotrexate or cytarabine, and with modifications to dose schedule of vincristine and steroids) followed by rituximab maintenance for 5 years resulted in a median PFS of 37 months with median OS not reached; the use of rituximab maintenance appeared to prolong PFS with acceptable toxicity.<sup>57</sup>

In a subsequent study that incorporated the proteasome inhibitor bortezomib into the modified R-hyperCVAD (VcR-CVAD regimen) followed by rituximab maintenance in patients with previously untreated MCL (n=30), the CR/CRu rate was 77%.<sup>58</sup> After a median follow-up of 42 months, median PFS and OS had not been reached. The 3-year PFS rate was 63%, and OS rate was 86%. This VcRCVAD regimen with maintenance rituximab was further evaluated in a larger phase II ECOG trial (E1405) in patients with previously untreated MCL (n=75).<sup>60</sup> The ORR in this trial was 95% with CR in 68% of patients. After induction therapy, patients proceeded with maintenance rituximab (n=44) or consolidation with hematopoietic stem cell transplant (HSCT) off protocol (n=22). After a median follow-up of 4.5 years, the 3-year PFS and OS rates were 72% and 88%, respectively. No differences in PFS or OS were seen between patients who went on to receive rituximab maintenance or HSCT.<sup>60</sup>

The European MCL Network recently conducted a phase III randomized trial in older patients (age >60 years not eligible for HDT/ASCR) with previously untreated MCL (n=560; 485 patients evaluable for

response) to evaluate induction with R-FC (rituximab, fludarabine and cyclophosphamide) versus R-CHOP, with a second randomization to maintenance with rituximab every 2 months (until relapse; thus, there was no set duration of maintenance rituximab) versus interferon-alfa (given until progression in both arms).<sup>59</sup> Response after induction therapy with R-CHOP and R-FC was similar (CR rate, 34% vs 40%; CR/CRu rate, 49% vs 53%; ORR, 86% vs 78%, respectively), but more patients progressed during R-FC treatment than with R-CHOP (14% vs 5%).

Median duration of response was similar between R-FC and R-CHOP arms (37 vs 36 months). OS (from start of induction) was significantly longer with R-CHOP compared with R-FC (Median OS, 67 vs 40 months; 4-year OS, 62% vs 47%;  $P=0.005$ ).<sup>59</sup> Grade 3 to 4 hematologic toxicities occurred more frequently with R-FC induction. Among the patients who responded to induction and underwent second randomization ( $n=316$ ), median remission duration was significantly improved with rituximab maintenance compared with interferon alfa (75 vs 27 months;  $P<.001$ ). After a median follow-up of 42 months, OS outcomes were not significantly different between the 2 maintenance arms (4-year OS: 79% with rituximab vs 67% with interferon alfa).<sup>59</sup> However, in the subgroup of patients treated with R-CHOP induction ( $n=184$ ), median OS (from end of induction) was significantly longer with rituximab compared with interferon alfa (not reached vs 64 months; 4-year OS: 87% vs 63%;  $P=0.005$ ). Moreover, grade 3 to 4 hematologic toxicities occurred more frequently with interferon alfa. Rituximab was associated with more frequent grade 1 to 2 infections.<sup>59</sup> This study suggests that for patients who are not candidates for HDT/ASCR as part of first-line therapy, R-CHOP induction followed by rituximab maintenance may offer the best chance to prolong remission duration. Given the positive outcomes reported in this study (with median duration of response exceeding 6 years with rituximab maintenance and a 4-year OS rate of 87% in patients treated with R-CHOP and rituximab maintenance), it is unknown whether first-line consolidation with HDT/ASCR provides an advantage over rituximab maintenance in patients of any age. At the present time, no data are available from randomized studies that would allow direct comparison of outcomes with these 2 different consolidation approaches.

### Relapsed or Refractory Disease

**Second-Line Therapy:** The treatment of patients with relapsed/refractory MCL remains a major challenge, as CR rates are generally low (<30%) and response durations are limited with available regimens.<sup>61</sup>

Bortezomib is a proteasome inhibitor with activity in patients with relapsed or refractory MCL,<sup>62-64</sup> and is currently approved for the treatment of patients with MCL that has relapsed after at least one prior therapy. FDA approval of this agent was based on data from the pivotal phase II PINNACLE trial of single-agent bortezomib in patients with relapsed/refractory MCL ( $n=155$ ; 141 evaluable patients).<sup>62</sup> In this trial, bortezomib induced an ORR of 33% (CR in 8%), with a median duration of response of 9 months.<sup>62</sup> Median time to progression (in all patients) was 6 months. Longer follow-up data also confirmed these initial findings; after a median follow-up time of 26 months, the median OS in all patients was 23.5 months and 35 months in responding patients.<sup>65</sup> Small studies have reported promising activity of bortezomib combined with rituximab in patients with relapsed/refractory MCL with heavy pretreatment.<sup>66,67</sup> In addition, bortezomib in combination with R-hyper-CVAD, with (as discussed previously) or without rituximab maintenance, is under investigation in previously untreated patients with MCL.<sup>58,68</sup>

Cladribine has shown activity as a single agent in patients with relapsed MCL.<sup>39,40</sup> In the trial conducted by the North Central Cancer Treatment group, the ORR and median PFS for patients with recurrent MCL ( $n=25$ ) were 46% (21% CR) and 5 months, respectively.<sup>39</sup>

Fludarabine-based combination regimens, with or without rituximab, have also shown activity in patients with relapsed or refractory MCL.<sup>69-71</sup> Results from a small pilot trial in patients with newly diagnosed and relapsed MCL (20 evaluable patients) showed that the combination of fludarabine, mitoxantrone, and rituximab (FMR) induced a CR rate of 90%, with a median duration of CR of 17 months.<sup>70</sup> In patients with MCL ( $n=66$ ) treated as part of a prospective randomized phase III study of the GLSG, the addition of rituximab to the combination of fludarabine, cyclophosphamide, and mitoxantrone (R-FCM), produced higher ORR (58% vs 46%) and CR rates (29% vs 0%) compared with FCM alone.<sup>71,72</sup> This trial included a second random-

ization to rituximab maintenance versus observation in patients who had a response to therapy. In the subgroup of patients with MCL who received R-FCM induction (n=47), rituximab maintenance resulted in a higher proportion of patients in remission beyond 2 years compared with observation only (45% vs 9%;  $P=0.049$ ); the median duration of remission was similar between maintenance and observation arms (14 vs 12 months).<sup>72</sup> In a phase III randomized trial from StiL, fludarabine combined with rituximab (FR) was compared with BR in patients with relapsed/refractory follicular or indolent lymphoma or MCL (208 evaluable patients; MCL histology in about 20%).<sup>73</sup> Following a protocol amendment, maintenance therapy with rituximab was also added in both treatment arms (n=40 only). The FR regimen resulted in an ORR and CR rate of 52.5% and 16%, respectively, which was significantly inferior to response rates with BR (ORR 83.5%; CR rate 38.5%). The median PFS with FR was 11 months, which was also significantly shorter compared with a median of 30 months observed with the BR regimen ( $P<.0001$ ).<sup>73</sup> However, no difference in median OS was observed between treatment arms after a median observation time of 33 months.

Bendamustine, as a single agent or in combination with rituximab, has shown promising results with acceptable toxicity in patients with heavy pre-treatment with relapsed or refractory indolent or mantle cell histologies as well as aggressive lymphomas.<sup>73,74</sup> In a phase II multicenter study, BR resulted in an ORR of 92% (41% CR) in patients with relapsed or refractory indolent lymphomas and MCL (n=67).<sup>74</sup> The median duration of response and PFS was 21 months and 23 months, respectively. Outcomes were similar for patients with indolent or mantle cell histologies. For the subgroup of patients with MCL histology (n=12), the ORR was 92% (42% CR; 17% CRu) and the median duration of response was 19 months.<sup>74</sup> As discussed previously, the phase III randomized trial from StiL showed superiority of the BR regimen compared with FR in patients with relapsed/refractory follicular or indolent lymphoma or MCL (208 evaluable patients; MCL histology in about 20%), with an ORR of 83.5% (38.5% CR) and median PFS of 30 months.<sup>73</sup> In a small multicenter phase II study that evaluated the combination of bendamustine and rituximab with bortezomib in patients with relapsed/refractory in-

dolent lymphomas or MCL (29 evaluable patients; MCL histology, n=7), the ORR was 83% (52% CR) and the 2-year PFS rate was 47%.<sup>75</sup> The ORR among the small subgroup of patients with MCL was 71%. Based on these results, this combination regimen is currently being evaluated in randomized trials conducted by the US cooperative groups.

Lenalidomide is an immunomodulating agent that has been evaluated as a single agent in patients with relapsed or refractory aggressive NHL in 2 phase II studies (NHL-002 and NHL-003).<sup>76-78</sup> In the subset analysis of patients with MCL (n=15) in the NHL-002 study, the ORR was 53% (20% CR).<sup>77</sup> The median duration of response and PFS were 14 months and 6 months, respectively. The subset analysis of patients with MCL (n=54) enrolled in the larger confirmatory study (NHL-003) also showed similar results with an ORR of 43% (17% CR).<sup>78</sup> An updated analysis from the NHL-003 study showed that in the relapsed/refractory MCL subgroup (n=57), the ORR with single-agent lenalidomide was 35% (12% CR/CRu) by independent central review at a median follow-up of 12 months.<sup>79</sup> The ORR by investigator review was 44% (21% CR/CRu). By central review, the median duration of response was 16 months and the median PFS was approximately 9 months.<sup>79</sup>

Additional phase II studies are specifically evaluating the role of single-agent lenalidomide in patients with relapsed/refractory MCL. In a phase II study in patients with relapsed/refractory MCL (n=26), lenalidomide (including low-dose lenalidomide maintenance in responding patients) resulted in an ORR of 31% with a median response duration of 22 months.<sup>80</sup> The median PFS was only 4 months. However, among the patients who received maintenance lenalidomide (n=11), the median PFS was 15 months.<sup>80</sup> In a larger multicenter phase II study (MCL-001) in patients who had relapse after or had disease refractory to bortezomib (n=134; median 4 prior therapies), lenalidomide as a single agent resulted in an ORR of 28% (7.5% CR/CRu) by independent central review.<sup>81</sup> All patients were previously treated with rituximab-containing regimens, and all had experienced relapse or had disease refractory to bortezomib. The median duration of response was 16.6 months. The median PFS and OS were 4 and 19 months, respectively. In the larger studies, the most common grade 3 or 4 toxicities with lenalidomide were myelosuppression (neutropenia in 43%/46%

and thrombocytopenia in 28%30%).<sup>79,81</sup>

Lenalidomide combined with rituximab is also under clinical evaluation. In a phase I/II study of a combination regimen with lenalidomide and rituximab in patients with relapsed/refractory MCL (36 evaluable patients), the ORR was 53% (31% CR).<sup>82</sup> The median duration of response was 18 months, and the median PFS (for all patients in the phase II portion) was 14 months. In an updated analysis of this study (n=52), the ORR was 57% (36% CR) among patients treated in the phase II portion (n=44); median duration of response was 19 months.<sup>83</sup> The median PFS was 11 months, and median OS was 24 months. The most common grade 3 or 4 toxicities included neutropenia (66%) and thrombocytopenia (23%).<sup>83</sup>

Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) involved in the Bcell signalling pathway and has shown promising activity in patients with B-cell malignancies.<sup>84</sup> In a phase I dose-escalation study in patients with relapsed and/or refractory B-cell malignancies (n=56; follicular lymphoma, 29%; chronic lymphocytic leukemia / SLL, 29%; MCL, 16%), ibrutinib given in a continuous or intermittent dosing schedule (until progression) resulted in an ORR of 60% (CR in 16%) among evaluable patients (n=50).<sup>84</sup> The median PFS was approximately 14 months. Among the subgroup of patients with MCL (n=9), response was observed in 7 patients, including a CR in 3 patients. Treatment with ibrutinib was well tolerated even with prolonged dosing (>6 months), with no dose-limiting toxicities and no significant myelosuppression; grade 3 or 4 adverse events were uncommon.<sup>84</sup> The fixed dose of 560 mg daily given continuously was well tolerated and resulted in full occupancy of the BTK target; thus, the recommended phase II dose was established as 560 mg daily. The results of a multicenter phase II study evaluating ibrutinib (560 mg continuous daily dosing until progression) in patients with relapsed or refractory MCL (n=115; median 3 prior therapies, range 1-5), including in patients previously treated with bortezomib, have been published.<sup>85</sup> Most patients (89%) had received previous rituximab-containing regimens, and 45% were refractory to last therapy before study enrollment. Most patients (72%) had advanced disease, and 49% had high-risk disease based on MIPI scores.<sup>85</sup> Among 111 evaluable patients, the estimated median follow-up was 15 months at analysis. The ORR was 68%

with a CR in 21% of patients. The median duration of response was 17.5 months. Among the subgroup of patients who were previously treated with bortezomib (n=48), the ORR was 67% with a CR in 23%. The response rates appeared to increase with longer duration of therapy. The estimated median PFS for all treated patients was approximately 14 months. Median OS has not yet been reached; the estimated OS rate at 18 months was 58%. The most common grade 3 or greater adverse events included neutropenia (16%), thrombocytopenia (11%), anemia (10%), pneumonia (6%), diarrhea (6%), fatigue (5%), and dyspnea (5%).<sup>85</sup> This study showed durable responses with single-agent ibrutinib with a favorable toxicity profile. Based on these data, ibrutinib (560 mg orally, once daily) was recently approved by the FDA for the treatment of patients with MCL who received at least one prior therapy.

**Second-Line Consolidation Therapy:** In patients with relapsed/refractory indolent NHL, allogeneic (HSCT) has resulted in decreased rates of disease recurrence compared with HDT/ASCR, but at the cost of a higher treatment-related mortality (TRM) rate.<sup>86,87</sup>

In an effort to reduce the TRM associated with allogeneic HSCT, the use of reduced-intensity conditioning (RIC) regimens has been explored. In a study that evaluated allogeneic HSCT using conventional myeloablative conditioning or RIC in patients with relapsed/refractory NHL (n=25), RIC (fludarabine-based regimens) was associated with a decreased TRM rate (17% vs 54%) and increased event-free survival (50% vs 23%) and OS (67% vs 23%) rates at 1 year compared with myeloablative regimens.<sup>88</sup> A multicenter retrospective study of RIC allogeneic HSCT in patients with relapsed/refractory low-grade NHL (n=73) also reported promising long-term outcomes with RIC (primarily using fludarabine-based regimens). In this study, the 3-year EFS and OS rates were 51% and 56%, respectively.<sup>89</sup> Although the 3-year relapse rate appeared low at 10%, the TRM rate was high, with a 3-year cumulative incidence of 40%.<sup>89</sup> Allogeneic HSCT using RIC has been evaluated as a consolidation strategy for patients in remission after treatment for relapsed/refractory MCL.<sup>47,90,91</sup> In patients with relapsed MCL treated with RIC allogeneic HSCT (n=18), the 3-year PFS and estimated 3-year OS rates were 82% and 85.5%, respectively; most patients in this study (89%) had chemosensitive disease.<sup>90</sup>

In another study, RIC allogeneic HSCT was evaluated in patients with relapsed/refractory MCL (n=33); 42% of these patients had undergone failed HDT/ASCR previously.<sup>91</sup> The 2-year disease-free survival and OS rates were 60% and 65%, respectively. The 2-year relapse rate was 9%; moreover, with a median follow-up of nearly 25 months, none of the patients who underwent transplant in a CR (n=13) experienced disease relapse.<sup>91</sup> The 2-year TRM rate in this study was 24%. In an analysis of patients with MCL treated with HSCT at the MD Anderson Cancer Center, the subgroup of patients with relapsed/refractory disease treated with RIC allogeneic HSCT (n=35) had favorable longterm outcomes.<sup>47</sup> Most of these patients (62%) were transplanted in remission (31% in second remission). The analysis reported a median PFS of 60 months, and 6-year PFS and OS rates of 46% and 53%, respectively. The TRM rates at 3 months and 1 year were 0% and 9%, respectively.<sup>47</sup>

## NCCN Recommendations for Stage I-II

### Recommendations for First-Line Therapy and Follow-up

Outside of a clinical trial, the NCCN Guidelines panel recommends RT (3036 Gy) alone or combination chemoimmunotherapy with or without RT. These recommendations are based on treatment principles in the absence of more definitive clinical data.

For patients with a CR, clinical follow-up should be conducted every 3 to 6 months for the first 5 years, and then on a yearly basis or as clinically indicated. If the patient received initial treatment with chemoimmunotherapy with or without RT, and experiences relapse after an initial CR (or the initial response is a PR or disease progression on first-line therapy), the patient should be treated with second-line therapy regimens recommended for stage II (bulky) or stage III-IV disease (see subsequent sections). If the patient received initial treatment with RT alone and has relapse after a CR (or the initial response is a PR or disease progression with RT alone), then the patient can be treated with first-line induction therapy (comprising chemoimmunotherapy regimens) recommended for stage II (bulky) and stage III-IV disease.

## NCCN Recommendations for Stage II (bulky) and Stage III-IV

### Recommendations for First-Line Therapy and Follow-up

In the absence of standard management for patients with advanced disease, patients should be referred for participation in prospective clinical trials. Similar to the management of patients with indolent lymphomas, patients with MCL often require highly individualized courses of care. Most patients with MCL will have advanced-stage disease and require systemic therapy. However, in highly selected patients with asymptomatic disease, close observation with deferred therapy is a reasonable option, especially for those with good performance status and lower risk scores on standard IPI.<sup>92</sup> The standard treatment regimen for MCL is not yet established. No prospective randomized studies comparing the various aggressive induction regimens for MCL have been published, although some randomized data exist for less intensive first-line treatment options (as previously discussed). Given the role of rituximab in the treatment of CD20-positive NHL, it is reasonable to consider rituximab-containing regimens for management of patients with advanced MCL. See MANT-A for the list of specific regimens recommended for initial induction therapy. All regimens recommended for induction therapy (except hyperCVAD + rituximab) included first-line consolidation with HDT/ASCR in published reports.

For patients with a CR to first-line therapy, participation in a clinical trial or HDT/ASCR is recommended for eligible patients (see subsequent section). For patients with a CR, clinical follow-up should be conducted every 3 to 6 months for the first 5 years, and then on a yearly basis or as clinically indicated. For patients with only a PR to first-line therapy, additional therapy (see second-line therapy regimens in later sections) may be considered in an effort to improve the quality of a response. If the patient experiences a CR (or improved PR) with additional therapy, consolidation with HDT/ASCR may be considered for eligible patients, as discussed previously. For patients who experience relapse after remission to first-line therapy, or for patients who experience disease progression during initial therapy, participation in clinical trials is preferred. In the absence of suitable clinical trials, secondline treatment options can be considered.

## Non-Hodgkin's Lymphomas, Version 4.2014

**Recommendations for First-Line Consolidation Therapy**

The panel recommends consolidation with HDT/ASCR for eligible patients in remission after first-line therapy, although no studies have compared maintenance rituximab with HDT/ASCR for patients in first CR. In general, patients will receive an aggressive induction regimen before consolidation; however, less-aggressive induction therapy followed by consolidation with HDT/ASCR or maintenance rituximab may also result in good long-term outcome.

For patients who are not candidates for HDT/ASCR and who are in remission after first-line therapy with R-CHOP, maintenance treatment with rituximab (every 8 weeks until disease progression) is recommended (category 1)<sup>59</sup>

**Recommendations for Second-Line Therapy**

The optimal approach to relapsed or refractory disease remains to be defined. Patients with relapsed disease after CR to induction therapy, those with only a PR to induction therapy, or those with progressive disease are appropriate candidates for clinical trials involving HDT/ASCR or allogeneic HSCT, immunotherapy with nonmyeloablative stem cell rescue or treatment with new agents. Based on the recent FDA approval, the panel has included ibrutinib as an option for second-line therapy for patients with relapsed or refractory disease.<sup>85</sup> Alternatively, in the absence of an appropriate clinical trial, these patients can be treated with secondline chemotherapy regimens (with or without rituximab) recommended for patients with DLBCL or any of the regimens listed on MANT-A for second-line therapy.

Allogeneic HSCT (with myeloablative or RIC regimens) is an appropriate option for patients with relapsed or refractory disease that is in remission after second-line therapy.<sup>47,90,91</sup>

**References**

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997;89:3909–3918.
2. Fisher RI, Dahlborg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. *Blood* 1995;85:1075–1082.
3. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison

of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. *Blood* 2000;95:2253–2261.

4. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. *Blood* 2010;116:953–961.
5. Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. *Blood* 2012;119:4939–4948.
6. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. *Blood* 2005;106:4315–4321.
7. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. *Blood* 2008;111:5683–5690.
8. Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. *Blood* 2013;121:1394–1402.
9. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. *Mod Pathol* 2010;23:105–112.
10. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. *Haematologica* 2009;94:1555–1562.
11. Zeng W, Fu K, Quintanilla-Fend L, et al. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. *Am J Surg Pathol* 2012;36:214–219.
12. Avet-Loiseau H, Garand R, Gaillard F, et al. Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. *Genes Chromosomes Cancer* 1998;23:175–182.
13. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. *Blood* 2008;111:2385–2387.
14. Garcia M, Romaguera JE, Inamdar KV, et al. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. *Cancer* 2009;115:1041–1048.
15. Hsi ED, Jung S, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. *Leuk Lymphoma* 2008;49:2081–2090.
16. Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. *Ann Oncol* 2010;21:133–139.
17. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. *Br J Haematol* 2005;131:29–38.
18. Koletsis T, Markou K, Ouzounidou S, et al. In situ mantle cell lymphoma in the nasopharynx. *Head Neck* 2013;35:E333–7.
19. Richard P, Vassallo J, Valmary S, et al. "In situ-like" mantle cell lymphoma: a report of two cases. *J Clin Pathol* 2006;59:995–996.
20. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. *Haematologica* 2012;97:270–278.

## Non-Hodgkin's Lymphomas, Version 4.2014

21. Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4th). Lyon: IARC; 2008:229–232.
22. Edlfsen KL, Greisman HA, Yi HS, et al. Early lymph node involvement by mantle cell lymphoma limited to the germinal center: report of a case with a novel “follicular in situ” growth pattern. *Am J Clin Pathol* 2011;136:276–281.
23. Adam P, Schiefer AI, Prill S, et al. Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. *Mod Pathol* 2012;25:1629–1636.
24. Carbone A, Santoro A. How I treat: diagnosing and managing “in situ” lymphoma. *Blood* 2011;117:3954–3960.
25. Romaguera JE, Medeiros LJ, Hagemaster FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. *Cancer* 2003;97:586–591.
26. Salar A, Juanpere N, Bellosillo B, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. *Am J Surg Pathol* 2006;30:1274–1280.
27. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. *J Clin Oncol* 1995;13:2819–2826.
28. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. *Ann Oncol* 2003;14:1555–1561.
29. Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. *Ann Oncol* 2008;19:1327–1330.
30. Lacasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. *Blood* 2012;119:2093–2099.
31. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. *J Clin Oncol* 2005;23:7013–7023.
32. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. *Br J Haematol* 2010;150:200–208.
33. Merli F, Luminari S, Ilariucci F, et al. Rituximab plus hyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. *Br J Haematol* 2012;156:346–353.
34. Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. *Ann Oncol* 2013;24:1587–1593.
35. Howard OM, Gribben JG, Neuberger DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. *J Clin Oncol* 2002;20:1288–1294.
36. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *J Clin Oncol* 2005;23:1984–1992.
37. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet* 2013;381:1203–1210.
38. Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. *J Clin Oncol* 2013;31:1442–1449.
39. Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. *Cancer* 2008;113:108–116.
40. Rummel MJ, Chow KU, Jager E, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. *Ann Oncol* 1999;10:115–117.
41. Spurgeon SE, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. *Leuk Lymphoma* 2011;52:1488–1494.
42. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. *J Clin Oncol* 1998;16:3803–3809.
43. Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. *Cancer* 2003;98:2630–2635.
44. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. *Leukemia* 2002;16:587–593.
45. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. *Blood* 2005;105:2677–2684.
46. Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. *Ann Hematol* 2007;86:101–105.
47. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. *Blood* 2009;113:4144–4152.
48. van 't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. *Br J Haematol* 2009;144:524–530.
49. Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. *Leuk Lymphoma* 2008;49:1062–1073.
50. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. *Br J Haematol* 2003;120:793–800.
51. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. *Blood* 2008;112:2687–2693.
52. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. *J Clin Oncol* 2009;27:6101–6108.

## Non-Hodgkin's Lymphomas, Version 4.2014

53. Pott C, Hoster E, Beldjord K, et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract]. *Blood* 2010;116:Abstract 965.
54. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL Net) [abstract]. *Blood* 2012;120:Abstract 151.
55. Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. *Blood* 2013;121:48–53.
56. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. *Br J Haematol* 2012;158:355–362.
57. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. *Ann Oncol* 2006;17:1418–1423.
58. Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. *Br J Haematol* 2011;155:190–197.
59. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. *N Engl J Med* 2012;367:520–531.
60. Chang JE, Li H, Smith MR, et al. Phase II study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1405). *Blood* 2014;123:1665–1673.
61. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. *Crit Rev Oncol Hematol* 2011;80:69–86.
62. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 2006;24:4867–4874.
63. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. *Ann Oncol* 2007;18:116–121.
64. O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. *Br J Haematol* 2009;145:34–39.
65. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. *Ann Oncol* 2009;20:520–525.
66. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. *Cancer* 2011;117:2442–2451.
67. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. *Haematologica* 2011;96:1008–1014.
68. Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-hyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. *Br J Haematol* 2010;151:47–53.
69. Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. *Leuk Lymphoma* 2001;42:1015–1022.
70. Levine AM, Tulpule A, Smith L, et al. Results of a pilot trial of fludarabine, mitoxantrone and Rituxan in mantle cell lymphoma [abstract]. *Blood* 2005;106:Abstract 945.
71. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood* 2004;104:3064–3071.
72. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). *Blood* 2006;108:4003–4008.
73. Rummel MJ, Kaiser U, Balsler C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas: final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. *Blood* 2010;116:Abstract 856.
74. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. *J Clin Oncol* 2008;26:4473–4479.
75. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. *Blood* 2011;117:2807–2812.
76. Wiernik PH, Lossos IS, Tusciano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 2008;26:4952–4957.
77. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. *Br J Haematol* 2009;145:344–349.
78. Reeder CB, Witzig TE, Zinzani PL, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003) [abstract]. *J Clin Oncol* 2009;27:Abstract 8569.
79. Zinzani PL, Vose JM, Czuczman MS, et al. Phase II multicenter study of the safety and efficacy of single-agent lenalidomide in subjects with relapsed/refractory mantle cell lymphoma: long-term follow-up analysis of the NHL-003 study [abstract]. *Blood* 2012;120:Abstract 2738.
80. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. *Br J Haematol* 2012;159:154–163.
81. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. *J Clin Oncol* 2013;31:3688–3695.
82. Wang L, Fayad L, Hagemeister FB, et al. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma [abstract]. *Blood* 2009;114:Abstract 2719.
83. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. *Lancet Oncol* 2012;13:716–723.

## Non-Hodgkin's Lymphomas, Version 4.2014

- 
- 84.** Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. *J Clin Oncol* 2013;31:88–94.
- 85.** Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med* 2013;369:507–516.
- 86.** Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. *Ann Oncol* 2003;14:737–744.
- 87.** van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. *Blood* 2003;102:3521–3529.
- 88.** Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. *Ann Oncol* 2002;13:135–139.
- 89.** Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). *Haematologica* 2007;92:627–634.
- 90.** Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. *J Clin Oncol* 2003;21:4407–4412.
- 91.** Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. *Blood* 2004;104:3535–3542.
- 92.** Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. *J Clin Oncol* 2009;27:1209–1213.

## Non-Hodgkin's Lymphomas, Version 4.2014

Individual Disclosure for the NCCN Non-Hodgkin's Lymphomas Panel					
Panel Member	Clinical Research Support/Data Safety Monitoring Board	Advisory Boards, Speakers Bureau, Expert Witness, or Consultant	Patent, Equity, or Royalty	Other	Date Completed
Jeremy S. Abramson, MD	Celgene Corporation; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Constellation, Inc.; Gilead Sciences, Inc.; Seattle Genetics, Inc.; and Pharmacyclics, Inc.	Janssen Pharmaceutica Products, LP; Millennium Pharmaceuticals, Inc.; Gilead Sciences, Inc.; and Spectrum Pharmaceuticals	None	None	8/23/14
Ranjana H. Advani, MD	Celgene Corporation; Genentech, Inc.; Janssen Pharmaceutica Products, LP; Millennium Pharmaceuticals, Inc.; Agensys, Inc.; Allos Therapeutics; Idera Pharmaceuticals; Seattle Genetics, Inc.; and Pharmacyclics, Inc.	Genentech, Inc.; Millennium Pharmaceuticals, Inc.; Clariant Diagnostic Services, Inc.; and Seattle Genetics, Inc.	None	None	5/2/14
C. Babis Andreadis, MD, MSCE	GlaxoSmithKline	Millennium Pharmaceuticals, Inc.; Spectrum Pharmaceuticals, Inc.; and Pharmacyclics, Inc.	Roche Laboratories, Inc.	None	5/28/14
Nancy Bartlett, MD	AstraZeneca Pharmaceuticals LP; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceutica Products, LP; MedImmune Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; Pfizer Inc.; and Pharmacyclics, Inc.	Seattle Genetics, Inc.	None	None	4/14/14
John C. Byrd, MD	None	Genentech, Inc.; and Pharmacyclics, Inc.	None	None	6/2/14
Myron S. Czuczman, MD	Celgene Corporation; Onyx Pharmaceuticals, Inc.; and Gilead Sciences, Inc.	Boehringer Ingelheim GmbH; Celgene Corporation; Algeta; Mundipharma International Ltd; and Teva Pharmaceutical Industries Ltd.	None	None	5/22/14
Luis E. Fayad, MD	Centocor, Inc.; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Laboratories, Inc.; sanofi-aventis U.S.; and Wyeth Pharmaceuticals	None	None	None	9/18/13
Richard I. Fisher, MD	None	Johnson & Johnson; Coherus BioSciences, Inc.; and Gilead Sciences, Inc.	None	None	5/5/14
Martha J. Glenn, MD	Amgen Inc.; Institutional DSMC; and sanofi-aventis U.S.	None	None	None	6/2/14
Leo I. Gordon, MD	None	None	None	None	6/3/14
Nancy Lee Harris, MD	Pharmacyclics, Inc.	None	None	None	5/19/14
Richard T. Hoppe, MD	None	Clariant Diagnostic Services, Inc.	None	None	5/19/14
Steven M. Horwitz, MD	Celgene Corporation; Millennium Pharmaceuticals, Inc.; Infinity Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; and Spectrum Pharmaceuticals, Inc.	Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Actelion Pharmaceuticals Ltd; Kyowa Hakko Kirin Co., Ltd.; and Spectrum Pharmaceuticals, Inc.	None	None	6/23/14
Christopher R. Kelsey, MD	Varian Medical Systems, Inc.	None	None	None	6/2/14
Youn H. Kim, MD	Eisai Inc.; Genentech, Inc.; Millennium Pharmaceuticals, Inc.; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; and SHAPE	Celgene Corporation; and Medicis Pharmaceutical	None	Eisai Inc.; and Millennium Pharmaceuticals, Inc.	6/5/14
Susan Krivacic, MPAff	None	None	None	None	5/6/14
Ann S. LaCasce, MD	None	GlaxoSmithKline	None	None	5/23/14
Auayporn Nademanee, MD	Celgene Corporation; and Seattle Genetics, Inc.	None	None	None	5/22/14
Pierluigi Porcu, MD	Infinity Pharmaceuticals; OncoMed Pharmaceuticals, Inc.; and Seattle Genetics, Inc.	Celgene Corporation; and Actelion Pharmaceuticals Ltd.	None	None	6/23/14
Oliver Press, MD, PhD	Genentech, Inc.; and Roche Laboratories, Inc.	Algeta; and BIND Therapeutics, Inc.	Emergent BioSolutions Inc.	None	4/7/14
Rachel Rabinovitch, MD	RTOG Data Safety and Monitoring Board	None	None	Accuray Incorporated	4/22/14
Nishitha Reddy, MD	Celgene Corporation	Celgene Corporation	None	None	11/21/13
Erin Reid, MD	Bristol-Myers Squibb Company; Janssen Pharmaceutica Products, LP; Millennium Pharmaceuticals, Inc.; AbbVie Inc.; AIDS Malignancy Consortium; CALGB/CTSUs; Isis Pharmaceuticals, Inc.; Pharmacyclics, Inc.; and Takeda Pharmaceuticals North America, Inc.	Seattle Genetics, Inc.	None	None	6/17/14
Ayman A. Saad, MD	None	IMS Consulting Group	None	None	6/26/14
Lubomir Sokol, MD, PhD	None	Alexion Pharmaceuticals, Inc.; Celgene Corporation; Janssen Pharmaceutica Products, LP; Onyx Pharmaceuticals, Inc.; and Spectrum Pharmaceuticals, Inc.	None	None	5/2/14
Lode J. Swinnen, MB, ChB	Abbott Laboratories	None	None	None	11/6/13
Christina Tsien, MD	None	None	None	None	5/27/14
Julie M. Vose, MD, MBA	Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Onyx Pharmaceuticals, Inc.; Incyte Corporation; Biotest Pharmaceuticals Corporation; Pharmacyclics, Inc.; and sanofi-aventis U.S.	None	None	None	6/3/14
William G. Wierda, MD, PhD	Abbott Laboratories; and GlaxoSmithKline	Celgene Corporation; Genentech, Inc.; and Roche Laboratories, Inc.	None	None	6/5/14
Joachim Yahalom, MD	None	None	None	None	8/18/14
Nadeem Zafar, MD	None	None	None	None	6/3/14
Andrew D. Zelenetz, MD, PhD	Abbott Laboratories; Boehringer Ingelheim GmbH; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Constellation Pharmaceuticals; Infinity Pharmaceuticals; Curis, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals; and Seattle Genetics, Inc.	Amgen Inc.; Celgene Corporation; Genentech, Inc.; Bullet Bio Technology; Cancer Genetics; Dr. Reddy's Laboratories; Emergent BioSolutions, Inc; Foundation Medicine; Gilead Sciences, Inc.; Hospira, Inc.; Roche Laboratories, Inc.; and sanofi-aventis U.S.	None	None	6/12/13

The NCCN guidelines staff have no conflicts to disclose.